Surgical vs TranscatheterFriday, July 24, 2026

A critical appraisal of "A novel survival prediction model after isolated surgical aortic valve replacement in the transcatheter aortic valve replacement era".

1 min read·By E. Nolan Beckett, MD·Source: General thoracic and cardiovascular surgery

From The Valve Wire

This is a critical appraisal, not original data.

Akhtar and Javaid examine a recently proposed six-variable model for predicting long-term survival after isolated SAVR in the TAVR era and identify substantive methodological weaknesses: variable selection driven by maximal 5-year C-statistic without formal sample size justification or shrinkage-based criteria, validation limited to internal resampling from the derivation registry, omission of frailty and key anatomical and comorbidity variables, no head-to-head comparison against established risk scores, and no decision curve analysis to establish clinical utility.

Prediction models built and validated within the same registry routinely overstate performance in the wild, and lifetime management decisions between SAVR and TAVR — now the central question the ESC 2025 guidelines address with a 70-year age threshold and the ACC/AHA 2020 guidelines address with age 65 and 80 anchors — demand externally validated tools that incorporate frailty.

A model without frailty cannot credibly guide the choice between operations whose comparative advantage in the elderly hinges on it.

Source Abstract

Maeda et al. recently proposed a model to predict long-term survival after isolated surgical aortic valve replacement (SAVR) in the transcatheter aortic valve replacement (TAVR) era. While the model shows encouraging discrimination and calibration, several methodological and clinical limitations may restrict its broader applicability. The authors selected the final six-variable model primarily on the basis of maximal five-year C-statistic, without formal sample size justification or contemporary shrinkage-based criteria. Validation was restricted to internal resampling within the same registry, limiting evidence for transportability. Important prognostic domains, notably frailty and key anatomical and comorbidity variables, were not incorporated, and performance was not directly compared with established risk scores. Reporting only partially aligns with modern prediction model guidelines and omits decision curve analysis, leaving clinical utility uncertain. Overall, the model represents a valuable step but requires methodological refinement and external validation before guiding lifetime management between SAVR and TAVR.EBM Rating: Level V evidence. The article represents expert opinion derived from the author's clinical experience and interpretation of existing literature, without original experimental, randomized, controlled, cohort, or comparative analytic data.

Authors: Akhtar I, Javaid MH

Read the Original

Full article at General thoracic and cardiovascular surgery

Open at General thoracic and cardiovascular surgery →

The Valve Wire summarizes; we link out to primary sources for verification.